METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY

Abstract: this disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a programmed death-1 (pd-1) receptor and inhibits pd-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a pd-1 receptor and inhibits pd-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a cytotoxic t-lymphocyte antigen-4 (ctla-4) and inhibits ctla-4 activity.

Inventor(s): Marina TSCHAIKA

CPC Classification: C07K16/2818 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154258